Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was explore the relationship between plasma concentration of angiotensin II (Ang II), Adrenomedulin (ADM) and adrenotensin (ADT) in patients with hypertension and LVH.
|
31217886 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
In the present study, the potential role of AHR signaling in the development of left ventricular hypertrophy and cardiac fibrosis by angiotensin II (Ang II) infusion was investigated in mice lacking the AHR gene (Ahr<sup>-/-</sup>).
|
31016362 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
In the present study, the potential role of AHR signaling in the development of left ventricular hypertrophy and cardiac fibrosis by angiotensin II (Ang II) infusion was investigated in mice lacking the AHR gene (Ahr<sup>-/-</sup>).
|
31016362 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
These trends were also observed in histological analysis, demonstrating that cardiac function tracking using in vivo and real-time 9.4T MR imaging provides valuable information about the cardiac remodeling induced by AngII and sRAGE in an AngII-induced LV hypertrophy mice model.
|
31186521 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronically instrumented pigs received angiotensin II infusion for4weeks to induce chronic hypertension (133 ± 7 mmHg vs 98 ± 5 mmHg for mean arterial pressure at Day 28 vs 0, respectively) and LV hypertrophy.
|
31051181 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, the potential role of AHR signaling in the development of left ventricular hypertrophy and cardiac fibrosis by angiotensin II (Ang II) infusion was investigated in mice lacking the AHR gene (Ahr<sup>-/-</sup>).
|
31016362 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eight chronically instrumented pigs receiving continuous angiotensin II infusion during 28days to induce chronic hypertension and LV hypertrophy.
|
29196088 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We challenged C57BL/6 adult male mice with an infusion of AngII (osmotic pumps; 2 mg/kg.day) to induce LVH.
|
30267750 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the possibility that RAGE-mediated signaling is involved in angiotensin II (Ang II)-induced cardiac left ventricular hypertrophy has yet to be investigated.
|
29796842 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
|
27722772 |
2017 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
In contrast to TAC, antagonizing the function of CTGF had no effect on LV dysfunction or LV hypertrophy in mice subjected to 4-week angiotensin II infusion.
|
24688123 |
2014 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
In contrast to TAC, antagonizing the function of CTGF had no effect on LV dysfunction or LV hypertrophy in mice subjected to 4-week angiotensin II infusion.
|
24688123 |
2014 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs.
|
20837116 |
2010 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs.
|
20837116 |
2010 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the induction of human cardiac fibroblasts (HCF) and human umbilical vein endothelial cells (HUVEC) with the LVH mediator angiotensin II enabled us to investigate uremic LVH progression in vitro.
|
19094982 |
2009 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We further unraveled robust increases in HCN2/HCN4 transcripts and protein levels, using real-time RT-PCR and Western blot analyses, in a rat model of left ventricular hypertrophy and in angiotensin II-induced neonatal ventricular hypertrophy.
|
19471099 |
2009 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
|
18679781 |
2008 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
|
18679781 |
2008 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen M235T and T174M polymorphisms have individually been associated with elevated levels of plasma angiotensinogen, hypertension, and left ventricular hypertrophy.
|
17145981 |
2007 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Angiotensinogen (AGT), the precursor of angiotensin II and a rate limiting factor in the renin-angiotensin system, is implicated in left ventricular hypertrophy, as angiotensin II is a potent stimulator of cardiac growth.
|
16280278 |
2005 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensinogen (AGT), the precursor of angiotensin II and a rate limiting factor in the renin-angiotensin system, is implicated in left ventricular hypertrophy, as angiotensin II is a potent stimulator of cardiac growth.
|
16280278 |
2005 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats.
|
14751847 |
2004 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats.
|
14751847 |
2004 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean arterial blood pressure.
|
14644620 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.
|
12640257 |
2003 |